Effect of the Cardiac Myosin Activator Omecamtiv Mecarbil on Ventricular Arrhythmias, Cardiac Arrest, and Sudden Death in Heart Failure With Reduced Ejection Fraction: The GALACTIC-HF Trial

Mitral Regurgitation in Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Clinical Evaluation of Drug-Drug Interactions With Aficamten

Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM Long-Term Study

Dipstick Proteinuria and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy

Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF

One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge

Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023

Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM